Af­ter Covid set­back, Val­ne­va lines up $100M for Pfiz­er-al­lied Ly­me dis­ease PhI­II

Val­ne­va has se­cured €102.9 mil­lion (around $99.9 mil­lion USD) in a share of­fer­ing to push for­ward its Pfiz­er-part­nered Ly­me dis­ease vac­cine and a jab for chikun­gun­ya that awaits an FDA de­ci­sion.

The French vac­cine mak­er large­ly snagged the near $100 mil­lion from Deep Track Cap­i­tal and lo­cal state-owned Bpifrance, the com­pa­ny said Tues­day night. The cap­i­tal in­jec­tion is near­ly equal to the amount Pfiz­er paid to nab eq­ui­ty in the com­pa­ny ear­li­er this sum­mer as part of the duo’s vac­cine tie-up.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.